Synlogic (SYBX) – Investment Analysts’ Weekly Ratings Changes

Synlogic (NASDAQ: SYBX) has recently received a number of price target changes and ratings updates:

  • 8/14/2019 – Synlogic was downgraded by analysts at Zacks Investment Research from a “buy” rating to a “hold” rating. According to Zacks, “Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company’s pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. “
  • 8/12/2019 – Synlogic had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $22.00 price target on the stock. They wrote, “We calculate an enterprise value of $820M, comprised of $620M for SYNB1020 in UCD and hyperammonemia and I/O portfolio. This yields a price objective of $22.00 per share, with approximately 37M fully-diluted shares outstanding as of mid-2020 (including exercise of approximately 2.5M outstanding options and all of the roughly 2.5M pre-funded warrants previously issued in the last private placement transaction). Risks include, but are not limited to: (1) feasibility issues with bridging the liquid to the solid oral formulation; (2) negative results from early trials; (3) slower-than-anticipated clinical testing; and (4) inability to obtain regulatory approvals.””
  • 8/9/2019 – Synlogic had its “outperform” rating reaffirmed by analysts at Wedbush. They now have a $20.00 price target on the stock.
  • 8/1/2019 – Synlogic was upgraded by analysts at ValuEngine from a “sell” rating to a “hold” rating.
  • 7/24/2019 – Synlogic was downgraded by analysts at ValuEngine from a “hold” rating to a “sell” rating.
  • 7/16/2019 – Synlogic was upgraded by analysts at Zacks Investment Research from a “hold” rating to a “buy” rating. They now have a $9.00 price target on the stock. According to Zacks, “Synlogic, Inc. engaged in the development of a novel class of living Synthetic Biotic(TM) medicines based on its proprietary drug discovery and development platform. The company’s pipeline includes Synthetic Biotic medicines for the treatment of rare genetic diseases such as Urea Cycle Disorder and Phenylketonuria. In addition, the company is leveraging the broad potential of its platform to create Synthetic Biotic medicines for the treatment of other diseases, such as liver disease, inflammatory and immune disorders and cancer. It is collaborating with AbbVie to develop Synthetic Biotic-based treatments for inflammatory bowel disease. Synlogic Inc., formerly known as Mirna Therapeutics Inc., is based in Cambridge, Massachusetts. “
  • 7/16/2019 – Synlogic had its price target raised by analysts at HC Wainwright from $20.00 to $22.00. They now have a “buy” rating on the stock.
  • 7/15/2019 – Synlogic had its price target raised by analysts at Piper Jaffray Companies from $16.00 to $20.00. They now have an “overweight” rating on the stock.
  • 7/15/2019 – Synlogic was given a new $25.00 price target on by analysts at Chardan Capital. They now have a “buy” rating on the stock.
  • 6/24/2019 – Synlogic had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $20.00 price target on the stock.

NASDAQ SYBX traded down $0.02 on Thursday, hitting $4.73. The company’s stock had a trading volume of 6,673 shares, compared to its average volume of 258,720. Synlogic Inc has a 52-week low of $4.57 and a 52-week high of $14.59. The company has a debt-to-equity ratio of 0.20, a quick ratio of 11.53 and a current ratio of 11.53. The firm’s 50-day simple moving average is $7.07. The firm has a market capitalization of $158.91 million, a price-to-earnings ratio of -2.33 and a beta of 2.39.

Synlogic (NASDAQ:SYBX) last released its quarterly earnings data on Thursday, August 8th. The biotechnology company reported ($0.45) earnings per share for the quarter, topping the consensus estimate of ($0.49) by $0.04. Synlogic had a negative return on equity of 38.75% and a negative net margin of 1,844.96%. The business had revenue of $0.35 million during the quarter, compared to analysts’ expectations of $0.96 million. As a group, sell-side analysts anticipate that Synlogic Inc will post -1.92 earnings per share for the current fiscal year.



Several large investors have recently made changes to their positions in the company. BlackRock Inc. boosted its position in Synlogic by 33.4% in the fourth quarter. BlackRock Inc. now owns 1,248,355 shares of the biotechnology company’s stock worth $8,750,000 after purchasing an additional 312,398 shares during the last quarter. Bank of New York Mellon Corp boosted its position in Synlogic by 12.1% in the fourth quarter. Bank of New York Mellon Corp now owns 56,774 shares of the biotechnology company’s stock worth $398,000 after purchasing an additional 6,129 shares during the last quarter. Northern Trust Corp boosted its position in Synlogic by 1.2% in the fourth quarter. Northern Trust Corp now owns 167,135 shares of the biotechnology company’s stock worth $1,172,000 after purchasing an additional 2,005 shares during the last quarter. Dimensional Fund Advisors LP boosted its position in Synlogic by 50.1% in the fourth quarter. Dimensional Fund Advisors LP now owns 316,656 shares of the biotechnology company’s stock worth $2,220,000 after purchasing an additional 105,628 shares during the last quarter. Finally, Geode Capital Management LLC boosted its position in Synlogic by 12.0% in the fourth quarter. Geode Capital Management LLC now owns 155,161 shares of the biotechnology company’s stock worth $1,087,000 after purchasing an additional 16,591 shares during the last quarter. 81.88% of the stock is owned by hedge funds and other institutional investors.

Synlogic, Inc a clinical-stage biopharmaceutical company, focuses on the discovery and development of synthetic biotic medicines to treat metabolic, inflammatory, and cancer diseases in the United States. Its lead therapeutic programs include SYNB1020, an oral therapy for the treatment of hyperammonemia, which includes patients with liver diseases, such as hepatic encephalopathy, as well as patients with urea cycle disorders; and SYNB1618, an oral therapy that is in Phase I/IIa clinical trial to treat phenylketonuria.

Further Reading: Why Net Income is Important to Investors

Receive News & Ratings for Synlogic Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Synlogic Inc and related companies with MarketBeat.com's FREE daily email newsletter.